The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis
Open accessAbstract
CONTEXT Magnetic resonance imaging (MRI), with or without MRI-targeted biopsy (MRI pathway), is an alternative test to systematic transrectal ultrasonography-guided biopsy in men suspected of having prostate cancer. At present, evidence on which test to use is insufficient to inform detailed evidence-based decision making. OBJECTIVE To determine the diagnostic accuracy of the index tests MRI only, MRI-targeted biopsy, MRI pathway, and systematic biopsy, as compared with template-guided biopsy (reference standard), in detecting clinically significant prostate cancer, defined as International Society of Urological Pathology grade 2 or higher, in biopsy-naive men or those with a prior-negative biopsy (or mix of both). EVIDENCE ACQUISITION We systematically searched the literature and considered for inclusion any cross-sectional study if it investigated (1) one or more index tests verified by the reference standard, and (2) paired testing of the MRI pathway with systematic biopsy. Quality and certainty of evidence were assessed by the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and Grading of Recommendations Assessment, Development and Evaluation, respectively. EVIDENCE SYNTHESIS Accuracy analyses: Using a baseline cancer prevalence of 30%, MRI pathway (sensitivity 0.72 [95% confidence interval {CI}: 0.60-0.82]; specificity 0.96 [0.94-0.98]; eight studies) may result in 216 (180-246) true positives, 28 (14-42) false positives, 672 (658-686) true negatives, and 84 (54-120) false negatives per 1000 men. Systematic biopsy (sensitivity 0.63 [0.19-0.93]; specificity 1.00 [0.91-1.00]; four studies) may result in 189 (57-279) true positives, 0 (0-63) false positives, 700 (637-700) true negatives, and 111 (21-243) false negatives per 1000 men. Agreement analyses: With a direct comparison of the MRI pathway with systematic biopsy concerning significant disease, we found pooled detection ratios of 1.05 (95% CI: 0.95-1.16; 20 studies) in biopsy-naive men and 1.44 (1.19-1.75; 10 studies) in men with a prior-negative biopsy. Concerning insignificant disease, we found detection ratios of 0.63 (95% CI: 0.54-0.74), and 0.62 (95% CI: 0.44-0.88), respectively. CONCLUSIONS MRI pathway had the most favourable outcome in significant and insignificant prostate cancer detection compared with systematic biopsy. The certainty in our findings was reduced by study limitations. PATIENT SUMMARY We reviewed recent advances in prostate biopsy by magnetic resonance imaging (MRI) guidance and targeting for prostate cancer detection in comparison with standard diagnosis by systematic biopsies. The findings of this Cochrane review suggest that MRI pathway is better than systematic biopsies in making a correct diagnosis of clinically important prostate cancer and reducing redundant biopsies and the detection of unimportant cancers substantially. However, MRI pathway still misses some men with important prostate cancer. Therefore, further research in this area is important.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., & Humphrey, P. A. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000530 · Cited by 3,236
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., Briganti, A., Budäus, L., Hellawell, G., Hindley, R. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801993 · Cited by 3,091
Self-citationPI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
Weinreb, J. C., Barentsz, J. O., Choyke, P. L., Cornud, F., Haider, M. A., Macura, K. J., Margolis, D., Schnall, M. D., Shtern, F., Tempany, C. M., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.052 · Cited by 2,951
ESUR prostate MR guidelines 2012
Barentsz, J. O., Richenberg, J., Clements, R., Choyke, P., Verma, S., Villeirs, G., Rouviere, O., Logager, V., & Fütterer, J. J. (2012) · European Radiology · doi:10.1007/s00330-011-2377-y · Cited by 2,438
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
Rouvière, O., Puech, P., Renard-Penna, R., Claudon, M., Roy, C., Mège-Lechevallier, F., Decaussin-Petrucci, M., Dubreuil-Chambardel, M., Magaud, L., Remontet, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30569-2 · Cited by 1,095
Fütterer, J. J., Briganti, A., De Visschere, P., Emberton, M., Giannarini, G., Kirkham, A., Taneja, S. S., Thoeny, H., Villeirs, G., & Villers, A. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.013 · Cited by 785
van der Leest, M., Cornel, E., Israël, B., Hendriks, R., Padhani, A. R., Hoogenboom, M., Zamecnik, P., Bakker, D., Setiasti, A. Y., Veltman, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.11.023 · Cited by 777
Dickinson, L., Ahmed, H. U., Allen, C., Barentsz, J. O., Carey, B., Futterer, J. J., Heijmink, S. W., Hoskin, P. J., Kirkham, A., Padhani, A. R., et al. (2011) · European Urology · doi:10.1016/j.eururo.2010.12.009 · Cited by 737
Cited by
Sandhu, S., Moore, C. M., Chiong, E., Beltran, H., Bristow, R. G., & Williams, S. G. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00950-8 · Cited by 583
de Rooij, M., Israël, B., Tummers, M., Ahmed, H. U., Barrett, T., Giganti, F., Hamm, B., Løgager, V., Padhani, A., Panebianco, V., et al. (2020) · European Radiology · doi:10.1007/s00330-020-06929-z · Cited by 324
Self-citation
Metadata
- Authors
- Drost, F.-J. H., Osses, D., Nieboer, D., Bangma, C. H., Steyerberg, E. W., Roobol, M. J., & Schoots, I. G.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 77
- Issue
- 1
- Pages
- 78-94
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2960844714
- Cited by
- 370
- References
- 31
- FWCI
- 9.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1016/j.eururo.2019.06.023
- The paper
- Drost, F.-J. H., Osses, D., Nieboer, D., Bangma, C. H., Steyerberg, E. W., Roobol, M. J., & Schoots, I. G. (2020). Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. European Urology. https://doi.org/10.1016/j.eururo.2019.06.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.